Its roles Owner Investor / Financier
Brenntag is a global distributor of chemicals and ingredients that connects producers and users across industrial and specialty markets. Headquartered in Germany, the company operates a broad network of warehouses, blending and repackaging sites, and application laboratories across Europe, the Americas, and Asia-Pacific.
Through its Essentials and Specialties businesses, Brenntag supplies commodity and high-value chemicals, offering services such as sourcing, logistics, safe handling, formulation support, technical and regulatory advice, and inventory and supply-chain management. End markets served include pharmaceuticals and life sciences, food and nutrition, personal care, coatings and construction, water treatment, mining, electronics, energy, and general manufacturing. Brenntag also partners with producers under exclusive and semi-exclusive distribution agreements and provides customized blends and solutions to meet specific performance and compliance requirements.
Also known as Brenntag AG and Brenntag Specialties.
chemXplore tracks 1 project involving Brenntag.
Adds specialty alumina grades for ceramics, polishing and other industrial uses across Mexico and Latin America (ex‑Brazil), extending an existing U.S. collaboration.
Brings cosmetic actives and specialty ingredients to Australia and New Zealand, paired with local distribution, technical formulation support and Innovation & Application Centers.
Exclusive global distribution of GMP‑grade biopharma vitamins for cell culture media; eight B‑vitamin products, multi‑pack sizes and CPHI Milano debut.
Board chair Thomas Leysen will retire; shareholders will vote on Richard Ridinger at an Extraordinary General Meeting on 19 Oct 2026.
Exclusive distribution expands Mexican personal-care lineup with nature-derived ingredients for skin, hair, color and oral formulations, plus improved supply reliability and formulation support.
Sales up 11% to €4.3bn; operating EBITDA +41% to €463m; gross margin rose to 26.9%. Guidance increased to €1,350–1,450m for 2026.
Co-branded GMP phosphates offered in ≤15 kg biopharma packs globally; original product line distributed in ≥25 kg packs across Europe.
Exclusive agreement transfers market development and distribution of GMP-grade REXIM amino acids across most of Europe to a regional distributor, effective July 1, 2026.
active all projects
